Ar­genx looks for quick la­bel ex­pan­sion for sub­cu­ta­neous Vyv­gart with PhII da­ta — shares soar

Less than a month af­ter ar­genx first land­ed ap­proval of the sub­cu­ta­neous ver­sion of its top drug, the Dutch biotech has notched an­oth­er win in an­oth­er rare dis­ease.

The pos­i­tive da­ta come from a Phase II study of Vyv­gart Hytru­lo in chron­ic in­flam­ma­to­ry de­myeli­nat­ing polyneu­ropa­thy (CIDP), where the drug slashed the risk of re­lapse by 61% ver­sus place­bo (p=0.000039), meet­ing the pri­ma­ry end­point in Stage B of the tri­al, which in­volved 221 pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER